Terpene Control in Scaleable Cannabinoid Medicinal Formulations

Abstract

The present invention administers a cannabinoid medication to a patient followed by observing one or more physiological responses in the patient during a first period of time when treating a medical condition. The cannabinoid medication may include one or more specific types of cannabinoids at a dosage level or may include a plurality of discrete formulations where each formulation includes masses of specific cannabinoids that may be used for treating one or more ailments.

1 . A formulation of matter including:
 two or more cannabinoids, wherein each of the one or more cannabinoids included in the formulation have a mass that corresponds to a cannabinoid dosage profile distributed in a volume of the formulation;   one or more terpenes, wherein each of the one or more terpenes are distributed in the volume of the formulation and have a mass corresponding to a terpene dosage profile, at least a portion of at least one of the one of the one or more terpenes was derived from a non-cannabinoid containing source, and the portion of the at least one terpene of the one or more terpenes was combined with the one or more cannabinoids such that the formulation includes a mass of the at least one terpene distributed in the volume of the formulation according to the terpene dosage profile.   
     
     
         2 . The formulation of matter of  claim 1 , wherein the masses of the two or more cannabinoids included in the formulation were from one or more cannabis plant extracts, and a cannabinoid content included in each of the one or more plant extracts were identified by laboratory testing 
     
     
         3 . The formulation of matter of  claim 2 , wherein the cannabinoid content in each of the one or more plant extracts includes at least one type of cannabinoid with a mass distributed in a unit volume of a first plant extract of the one or more plant extracts. 
     
     
         4 . The formulation of matter of  claim 2 , wherein the one or more plant extracts and the portion of the at least one terpene were combined when making the formulation according to a volumetric equation. 
     
     
         5 . The formulation of matter of  claim 1 , wherein the portion of the at least one terpene is at least one of myrcene, limonene, or beta caryophyllene. 
     
     
         6 . The formulation of matter of  claim 1 , wherein the one or more cannabinoids included in the formulation include at least three different types of cannabinoids according to the cannabinoids profile. 
     
     
         7 . The formulation of matter of  claim 6 , further comprising a plurality of discrete cannabinoid formulations that scale in a series of steps, the scaling in the series of steps changes such that a mass of at least a first cannabinoid type of the at least three different types of cannabinoids scales according to at least an exponential function over the series of steps. 
     
     
         8 . The formulation of matter of  claim 7 , wherein each of the discrete cannabinoid formulations are included in at least one of a pill, a capsule, a suppository, or a tincture. 
     
     
         9 . A formulation of matter comprising of a plurality of discrete cannabinoid formulations, wherein a mass of at least one cannabinoid of three of more cannabinoid types change at least according to an exponential function in a series of steps, each of the discrete cannabinoid formulations are included in at least one of a pill, a capsule, a suppository, or a tincture. 
     
     
         10 . The formulation of  claim 9 , wherein each of the discrete cannabinoid formulations include at a mass of at least one of tetrahydrocannabinol (THC), cannabidiol (CBD), and cannabigerol (CBG).